[HTML][HTML] Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis

F Traina, V Visconte, AM Jankowska, H Makishima… - 2012 - journals.plos.org
F Traina, V Visconte, AM Jankowska, H Makishima, CL O'Keefe, P Elson, Y Han, FH Hsieh…
2012journals.plos.org
We hypothesized that analysis of single nucleotide polymorphism arrays (SNP-A) and new
molecular defects may provide new insight in the pathogenesis of systemic mastocytosis
(SM). SNP-A karyotyping was applied to identify recurrent areas of loss of heterozygosity
and bidirectional sequencing was performed to evaluate the mutational status of TET2,
DNMT3A, ASXL1, EZH2, IDH1/IDH2 and the CBL gene family. Overall survival (OS) was
analyzed using the Kaplan-Meier method. We studied a total of 26 patients with SM. In 67 …
We hypothesized that analysis of single nucleotide polymorphism arrays (SNP-A) and new molecular defects may provide new insight in the pathogenesis of systemic mastocytosis (SM). SNP-A karyotyping was applied to identify recurrent areas of loss of heterozygosity and bidirectional sequencing was performed to evaluate the mutational status of TET2, DNMT3A, ASXL1, EZH2, IDH1/IDH2 and the CBL gene family. Overall survival (OS) was analyzed using the Kaplan-Meier method. We studied a total of 26 patients with SM. In 67% of SM patients, SNP-A karyotyping showed new chromosomal abnormalities including uniparental disomy of 4q and 2p spanning TET2/KIT and DNMT3A. Mutations in TET2, DNMT3A, ASXL1 and CBL were found in 23%, 12%, 12%, and 4% of SM patients, respectively. No mutations were observed in EZH2 and IDH1/IDH2. Significant differences in OS were observed for SM mutated patients grouped based on the presence of combined TET2/DNMT3A/ASXL1 mutations independent of KIT (P = 0.04) and sole TET2 mutations (P<0.001). In conclusion, TET2, DNMT3A and ASXL1 mutations are also present in mastocytosis and these mutations may affect prognosis, as demonstrated by worse OS in mutated patients.
PLOS